Jay Moyes Net Worth

The estimated Net Worth of Jay M Moyes is at least $1.34 Million dollars as of 13 June 2024. Mr. Moyes owns over 22,000 units of Puma Biotechnology Inc stock worth over $53,305 and over the last 22 years he sold PBYI stock worth over $926,818. In addition, he makes $357,201 as Lead Independent Director at Puma Biotechnology Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Moyes PBYI stock SEC Form 4 insiders trading

Jay has made over 25 trades of the Puma Biotechnology Inc stock since 2005, according to the Form 4 filled with the SEC. Most recently he sold 22,000 units of PBYI stock worth $73,480 on 13 June 2024.

The largest trade he's ever made was exercising 28,196 units of Puma Biotechnology Inc stock on 13 September 2007 worth over $286,471. On average, Jay trades about 4,725 units every 112 days since 2003. As of 13 June 2024 he still owns at least 21,322 units of Puma Biotechnology Inc stock.

You can see the complete history of Mr. Moyes stock trades at the bottom of the page.

Jay Moyes biography

Jay M. Moyes CPA serves as Lead Independent Director of the Company. Mr. Moyes has served as the Chief Financial Officer of Sera Prognostics, Inc., a private clinical-stage biotechnology company focused on improving maternal and neonatal health through innovative biomarker approaches, since March 2020. Mr. Moyes has been a member of the board of directors of Achieve Life Sciences, Inc., a public specialty pharmaceutical company, since August 2017. He has been a member of the board of directors of Biocardia, Inc., a publicly held cardiovascular regenerative medicine company, since January 2011. Mr. Moyes served as a member of the board of directors of Predictive Technology Group, Inc., a public molecular diagnostics and regenerative medicine company, from February 2019 to December 2019. Mr. Moyes was a director of Integrated Diagnostics, Inc., a privately held molecular diagnostics company from March 2011 to November 2016. Mr. Moyes was a member of the board of directors of Osiris Therapeutics, Inc., a public bio-surgery company, from May 2006 until December 2017 and Amedica Corporation, a public orthopedic implant company, from November 2012 to August 2014. He served as Chief Financial Officer of Amedica from October 2013 to August 2014. From May 2008 through July 2009, Mr. Moyes served as the Chief Financial Officer of XDx (now CareDx), Inc., a privately held molecular diagnostics company. Prior to that, Mr. Moyes served as the Chief Financial Officer of Myriad Genetics, Inc., a public healthcare diagnostics company, from June 1996 until November 2007, and as its Vice President of Finance from July 1993 until July 2005. From 1991 to 1993, Mr. Moyes served as Vice President of Finance and Chief Financial Officer of Genmark, Inc., a privately held genetics company. Mr. Moyes held various positions with the accounting firm of KPMG LLP from 1979 through 1991, most recently as a Senior Manager. He holds an M.B.A. from the University of Utah, a B.A. in economics from Weber State University, and is formerly a Certi

What is the salary of Jay Moyes?

As the Lead Independent Director of Puma Biotechnology Inc, the total compensation of Jay Moyes at Puma Biotechnology Inc is $357,201. There are 11 executives at Puma Biotechnology Inc getting paid more, with Alan H. Auerbach having the highest compensation of $5,693,423.

How old is Jay Moyes?

Jay Moyes is 66, he's been the Lead Independent Director of Puma Biotechnology Inc since 2018. There are no older and 15 younger executives at Puma Biotechnology Inc.

What's Jay Moyes's mailing address?

Jay's mailing address filed with the SEC is C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES, CA, 90024.

Insiders trading at Puma Biotechnology Inc

Over the last 13 years, insiders at Puma Biotechnology Inc have traded over $168,440,369 worth of Puma Biotechnology Inc stock and bought 2,655,298 units worth $48,866,148 . The most active insiders traders include Capital Partners Gp, L.L.C...., Steven Lo, and Troy Edward Wilson. On average, Puma Biotechnology Inc executives and independent directors trade stock every 18 days with the average trade being worth of $60,225. The most recent stock trade was executed by Michael Patrick Miller on 12 August 2024, trading 23,358 units of PBYI stock currently worth $81,519.

What does Puma Biotechnology Inc do?

we focus on in-licensing innovative drug candidates that are undergoing or have already completed initial clinical testing for the treatment of various forms of cancer and then seek to further develop these drug candidates for commercial use.

Complete history of Mr. Moyes stock trades at Myriad Genetics, Puma Biotechnology Inc, Achieve Life Sciences, and BioCardia

Puma Biotechnology Inc executives and stock owners

Puma Biotechnology Inc executives and other stock owners filed with the SEC include:

• Alan H. Auerbach,
  Founder, Chairman, Pres, CEO & Sec.
• Jeffrey Jerome Ludwig,
  Chief Commercial Officer
• Alan Auerbach,
  Chairman of the Board, President, Chief Executive Officer
• Douglas Hunt B.Sc., FRAPS,
  Sr. VP of Regulatory Affairs, Medical Writing & Project Management
• Maximo F. Nougues,
  CFO & Principal Accounting Officer
• Douglas Hunt,
  Senior Vice President, Regulatory Affairs, Medical Writing and Project Management
• Richard Bryce,
  Chief Medical and Scientific Officer
• Ann Miller,
  Independent Director
• Dr. Richard P. Bryce,
  Chief Medical & Scientific Officer
• Maximo Nougues,
  Chief Financial Officer
• Hugh O Dowd,
  Independent Director
• Jay Moyes,
  Lead Independent Director
• Troy Wilson,
  Independent Director
• Adrian Senderowicz,
  Independent Director
• Michael Miller,
  Independent Director
• Mariann Ohanesian,
  IR Contact Officer
• Brian Stuglik,
  Director
• Dr. Alvin F. Wong,
  Chief Scientific Officer
• Charon Spencer Sr.,
  VP of HR
• Steven Lo,
  Chief Commercial Officer
• Capital Partners Gp, L.L.C....,
  
• Robert Charnas,
  
• Richard Benton Phillips,
  SEE REMARKS
• Charles R Eyler,
  SEE REMARKS
• Frank Zavrl,
  Director
• Thomas Malley,
  Director
• Jeffrey Jerome Ludwig,
  Chief Commercial Officer
• Alvin F Wong,
  Chief Scientific Officer
• Allison Dorval,
  Director
• Alessandra Cesano,
  Director